{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:56:11Z","timestamp":1787025371325,"version":"build-2736575974"},"reference-count":19,"publisher":"S.C. JURNALUL PENTRU MEDICINA SI VIATA S.R.L","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMedLife"],"DOI":"10.25122\/jml-2023-0397","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:02:03Z","timestamp":1724025723000},"page":"63-66","source":"Crossref","is-referenced-by-count":6,"title":["Laboratory predictors of sickle cell disease severity: a cross-sectional study"],"prefix":"10.25122","volume":"17","author":[{"given":"Mortadah","family":"Alsalman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Medicine, College of Medicine, King Faisal University, Alahsa, Saudi Arabia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10755","published-online":{"date-parts":[[2024,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"100580","DOI":"10.1016\/j.blre.2019.05.004","article-title":"Sickle cell disease: Clinical presentation and management of a global health challenge","volume":"37","author":"Houwing ME, de Pagter PJ, van Beers EJ, Biemond BJ, Rettenbacher E, Rijneveld AW","year":"2019","unstructured":"1. Houwing ME, de Pagter PJ, van Beers EJ, Biemond BJ, Rettenbacher E, Rijneveld AW, Sickle cell disease: Clinical presentation and management of a global health challenge, Blood Rev, 2019;37100580","journal-title":"Blood Rev"},{"issue":"9","key":"ref2","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3324\/haematol.2018.207357","article-title":"Emerging disease-modifying therapies for sickle cell disease","volume":"104","author":"Carden MA, Little J","year":"2019","unstructured":"2. Carden MA, Little J, Emerging disease-modifying therapies for sickle cell disease, Haematologica, 2019;104(9):1710-1719","journal-title":"Haematologica"},{"issue":"3","key":"ref3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4103\/0256-4947.81540","article-title":"Epidemiology of sickle cell disease in Saudi Arabia","volume":"31","author":"Jastaniah W","year":"2011","unstructured":"3. Jastaniah W, Epidemiology of sickle cell disease in Saudi Arabia, Ann Saudi Med, 2011;31(3):289-93","journal-title":"Ann Saudi Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/IJGM.S393233","article-title":"The Burden of Sickle Cell Disease in Saudi Arabia: A Single-Institution Large Retrospective Study","volume":"16","author":"Bin Zuair A, Aldossari S, Alhumaidi R, Alrabiah M, Alshabanat A","year":"2023","unstructured":"4. Bin Zuair A, Aldossari S, Alhumaidi R, Alrabiah M, Alshabanat A, The Burden of Sickle Cell Disease in Saudi Arabia: A Single-Institution Large Retrospective Study, Int J Gen Med, 2023;16161-171","journal-title":"Int J Gen Med"},{"issue":"10091","key":"ref5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","article-title":"Sickle cell disease","volume":"390","author":"Ware RE, de Montalembert M, Tshilolo L, Abboud MR","year":"2017","unstructured":"5. Ware RE, de Montalembert M, Tshilolo L, Abboud MR, Sickle cell disease, Lancet, 2017;390(10091):311-323","journal-title":"Lancet"},{"issue":"1","key":"ref6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1182\/asheducation-2017.1.546","article-title":"Targeting novel mechanisms of pain in sickle cell disease","volume":"2017","author":"Tran H, Gupta M, Gupta K","year":"2017","unstructured":"6. Tran H, Gupta M, Gupta K, Targeting novel mechanisms of pain in sickle cell disease, Hematology Am Soc Hematol Educ Program, 2017;2017(1):546-555","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/asheducation-2017.1.440","article-title":"Evolving treatment paradigms in sickle cell disease","volume":"2017","author":"Jagadeeswaran R, Rivers A","year":"2017","unstructured":"7. Jagadeeswaran R, Rivers A, Evolving treatment paradigms in sickle cell disease, Hematology Am Soc Hematol Educ Program, 2017;2017(1):440-446","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"ref8","doi-asserted-by":"publisher","first-page":"e1915374","DOI":"10.1001\/jamanetworkopen.2019.15374","article-title":"Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease","volume":"2","author":"Lubeck D, Agodoa I, Bhakta N, Danese M, Pappu K, Howard R","year":"2019","unstructured":"8. Lubeck D, Agodoa I, Bhakta N, Danese M, Pappu K, Howard R, Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease, JAMA Netw Open, 2019;2(11):e1915374","journal-title":"JAMA Netw Open"},{"issue":"1","key":"ref9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1182\/hematology.2022000371","article-title":"Long-term health effects of curative therapy for sickle cell disease","volume":"2022","author":"Fitzhugh CD","year":"2022","unstructured":"9. Fitzhugh CD, Long-term health effects of curative therapy for sickle cell disease, Hematology, 2022;2022(1):266-271","journal-title":"Hematology"},{"issue":"8","key":"ref10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/ajh.23232","article-title":"Genetic modifiers of sickle cell disease","volume":"87","author":"Steinberg MH, Sebastiani P","year":"2012","unstructured":"10. Steinberg MH, Sebastiani P, Genetic modifiers of sickle cell disease, Am J Hematol, 2012;87(8):795-803","journal-title":"Am J Hematol"},{"issue":"9","key":"ref11","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E","year":"2017","unstructured":"11. Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, Gene therapy in a patient with sickle cell disease, N Engl J Med, 2017;376(9):848-855","journal-title":"N Engl J Med"},{"issue":"1","key":"ref12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.2022.10233","article-title":"Sickle Cell Disease: A Review","volume":"328","author":"Kavanagh PL, Fasipe TA, Wun T","year":"2022","unstructured":"12. Kavanagh PL, Fasipe TA, Wun T, Sickle Cell Disease: A Review, JAMA, 2022;328(1):57-68","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.2147\/CEOR.S276121","article-title":"Development of a Severity Classification System for Sickle Cell Disease","volume":"12","author":"Shah N, Beenhouwer D, Broder MS, Bronte-Hall L, De Castro LM, Gibbs SN","year":"2020","unstructured":"13. Shah N, Beenhouwer D, Broder MS, Bronte-Hall L, De Castro LM, Gibbs SN, Development of a Severity Classification System for Sickle Cell Disease, Clinicoecon Outcomes Res, 2020;12625-633","journal-title":"Clinicoecon Outcomes Res"},{"issue":"9","key":"ref14","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3324\/haematol.2014.120030","article-title":"Environmental determinants of severity in sickle cell disease","volume":"100","author":"Tewari S, Brousse V, Piel FB, Menzel S, Rees DC","year":"2015","unstructured":"14. Tewari S, Brousse V, Piel FB, Menzel S, Rees DC, Environmental determinants of severity in sickle cell disease, Haematologica, 2015;100(9):1108-16","journal-title":"Haematologica"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/1756-0500-5-396","article-title":"Haematological values in homozygous sickle cell disease in steady state and haemoglobin phenotypes AA controls in Lagos, Nigeria","volume":"5","author":"Akinbami A, Dosunmu A, Adediran A, Oshinaike O, Adebola P, Arogundade O","year":"2012","unstructured":"15. Akinbami A, Dosunmu A, Adediran A, Oshinaike O, Adebola P, Arogundade O, Haematological values in homozygous sickle cell disease in steady state and haemoglobin phenotypes AA controls in Lagos, Nigeria, BMC Res Notes, 2012;5396","journal-title":"BMC Res Notes"},{"issue":"8","key":"ref16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.4103\/ijccm.IJCCM_49_18","article-title":"The Platelet Count and its Implications in Sickle Cell Disease Patients Admitted for Intensive Care","volume":"22","author":"Shome DK, Jaradat A, Mahozi AI, Sinan AS, Ebrahim A, Alrahim M","year":"2018","unstructured":"16. Shome DK, Jaradat A, Mahozi AI, Sinan AS, Ebrahim A, Alrahim M, The Platelet Count and its Implications in Sickle Cell Disease Patients Admitted for Intensive Care, Indian J Crit Care Med, 2018;22(8):585-590","journal-title":"Indian J Crit Care Med"},{"issue":"2","key":"ref17","first-page":"6267","article-title":"Haematological values in sickle cell anaemia in steady state and during vaso-occlusive crisis in Benin City, Nigeria","volume":"4","author":"Omoti CE","year":"2005","unstructured":"17. Omoti CE, Haematological values in sickle cell anaemia in steady state and during vaso-occlusive crisis in Benin City, Nigeria, Ann Afr Med, 2005;4(2):6267Available from: https:\/\/www.ajol.info\/index.php\/aam\/article\/view\/8344","journal-title":"Ann Afr Med"},{"issue":"2","key":"ref18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/bjh.15021","article-title":"Fetal haemoglobin induction in sickle cell disease","volume":"180","author":"Paikari A, Sheehan VA","year":"2018","unstructured":"18. Paikari A, Sheehan VA, Fetal haemoglobin induction in sickle cell disease, Br J Haematol, 2018;180(2):189-200","journal-title":"Br J Haematol"},{"issue":"3","key":"ref19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2018-11-887679","article-title":"TMX1: a new vascular thiol isomerase","volume":"133","author":"Hogg PJ","year":"2019","unstructured":"19. Hogg PJ, TMX1: a new vascular thiol isomerase, Blood, 2019;133(3):188-190","journal-title":"Blood"}],"container-title":["Journal of Medicine and Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/medandlife.org\/all-issues\/2024\/issue-1-2024\/original-article-issue-1-2024\/laboratory-predictors-of-sickle-cell-disease-severity-a-cross-sectional-study\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:03:02Z","timestamp":1724025782000},"score":1,"resource":{"primary":{"URL":"https:\/\/medandlife.org\/all-issues\/2024\/issue-1-2024\/original-article-issue-1-2024\/laboratory-predictors-of-sickle-cell-disease-severity-a-cross-sectional-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["JMedLife-17-063"],"URL":"https:\/\/doi.org\/10.25122\/jml-2023-0397","relation":{},"ISSN":["1844-3117"],"issn-type":[{"value":"1844-3117","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}